Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Next-generation Sequencing Services Market

ID: MRFR/MRO/65604-HCR
200 Pages
Garvit Vyas
December 2024

Next-generation Sequencing Services Market Research Report By End Use (Academic Research, Pharmaceutical Companies, Biotechnology Firms, Clinical Laboratories, Healthcare Institutions), By Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Other Technologies), By Application (Clinical Diagnostics, Drug Discovery, Genomics Research, Agricultural Biotechnology, Personalized Medicine) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2035.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Next-generation Sequencing Services Market Infographic
Purchase Options

Next-generation Sequencing Services Market Summary

As per MRFR analysis, the Next-generation Sequencing Services Market was estimated at 18.0 USD Billion in 2024. The Next-generation Sequencing Services industry is projected to grow from 19.36 USD Billion in 2025 to 40.0 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.53% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Next-generation Sequencing Services Market is poised for substantial growth driven by technological advancements and increasing demand for personalized medicine.

  • North America remains the largest market for next-generation sequencing services, driven by robust healthcare infrastructure and research funding.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in genomic research and healthcare innovation.
  • Clinical diagnostics continues to dominate the market, while personalized medicine is rapidly gaining traction as a key growth segment.
  • Technological advancements in sequencing and the rising prevalence of genetic disorders are significant drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 18.0 (USD Billion)
2035 Market Size 40.0 (USD Billion)
CAGR (2025 - 2035) 7.53%

Major Players

Illumina (US), Thermo Fisher Scientific (US), BGI Genomics (CN), Roche (CH), Agilent Technologies (US), Qiagen (DE), PerkinElmer (US), Oxford Nanopore Technologies (GB), Genomatix (DE)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Next-generation Sequencing Services Market Trends

The Next-generation Sequencing Services Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and an increasing demand for genomic data. This market encompasses a wide array of services, including sequencing, data analysis, and bioinformatics, which are essential for various applications such as personalized medicine, drug discovery, and genetic research. The integration of artificial intelligence and machine learning into sequencing processes appears to enhance data interpretation and streamline workflows, potentially leading to more efficient outcomes. Furthermore, the growing emphasis on precision medicine and the need for tailored therapeutic strategies are driving the adoption of next-generation sequencing technologies across healthcare sectors. In addition to technological advancements, the Next-generation Sequencing Services Market is influenced by collaborative efforts among academic institutions, research organizations, and biotechnology companies. These partnerships seem to foster innovation and accelerate the development of novel sequencing applications. Moreover, regulatory frameworks are evolving to accommodate the rapid pace of innovation, which may facilitate market growth. As the demand for genomic insights continues to rise, the market is likely to expand, offering new opportunities for stakeholders involved in sequencing services and related fields. Overall, the Next-generation Sequencing Services Market is poised for substantial growth, driven by technological innovation and collaborative initiatives that enhance research capabilities and clinical applications.

Technological Advancements in Sequencing

The Next-generation Sequencing Services Market is witnessing a surge in technological innovations that enhance sequencing accuracy and efficiency. New methodologies, such as single-cell sequencing and long-read sequencing, are emerging, allowing for more comprehensive genomic analyses. These advancements may lead to improved diagnostic capabilities and a deeper understanding of complex diseases.

Growing Demand for Personalized Medicine

There is an increasing focus on personalized medicine within the Next-generation Sequencing Services Market. As healthcare shifts towards tailored treatment approaches, the need for precise genomic information becomes paramount. This trend suggests that sequencing services will play a crucial role in developing individualized therapies and improving patient outcomes.

Collaborative Research Initiatives

The Next-generation Sequencing Services Market is benefiting from collaborative research efforts among various stakeholders. Partnerships between academic institutions, biotechnology firms, and healthcare providers appear to drive innovation and expand the application of sequencing technologies. Such collaborations may enhance the development of new methodologies and foster a more integrated approach to genomic research.

Next-generation Sequencing Services Market Drivers

Collaborative Research Initiatives

Collaborative research initiatives are significantly influencing the Next-generation Sequencing Services Market. Partnerships among academic institutions, research organizations, and biotechnology companies are fostering innovation and accelerating the pace of genomic research. These collaborations often lead to large-scale projects that leverage next-generation sequencing technologies to address complex biological questions. For example, initiatives aimed at understanding rare diseases or cancer genomics are increasingly utilizing these advanced sequencing services to generate comprehensive datasets. The market is witnessing a surge in funding for such collaborative efforts, with public and private sectors investing heavily in genomic research. This collaborative environment not only enhances the quality of research but also drives the adoption of next-generation sequencing technologies across various fields, including agriculture and environmental science.

Rising Investment in Genomic Research

The Next-generation Sequencing Services Market is benefiting from a notable increase in investment in genomic research. Governments, private investors, and venture capitalists are recognizing the potential of genomics to transform healthcare and are allocating substantial resources to support research initiatives. This influx of funding is facilitating the development of advanced sequencing technologies and expanding the capabilities of existing platforms. Market data suggests that investment in genomics is expected to reach unprecedented levels, with billions of dollars being funneled into research projects and startups focused on next-generation sequencing applications. This financial backing not only accelerates innovation but also enhances the accessibility of sequencing services, thereby driving market growth and fostering a more robust research ecosystem.

Increased Demand for Personalized Medicine

The rising demand for personalized medicine is a pivotal driver for the Next-generation Sequencing Services Market. As healthcare shifts towards more individualized treatment approaches, the need for precise genomic information becomes paramount. Next-generation sequencing provides comprehensive insights into genetic variations, enabling tailored therapies that align with a patient's unique genetic makeup. This trend is underscored by the increasing prevalence of genetic disorders and the growing emphasis on preventive healthcare. Market data indicates that the personalized medicine segment is expected to account for a substantial share of the overall market, with projections suggesting it could reach several billion dollars by the end of the decade. Consequently, the integration of next-generation sequencing into clinical workflows is likely to accelerate, fostering innovation in drug development and therapeutic strategies.

Growing Applications in Clinical Diagnostics

The expanding applications of next-generation sequencing in clinical diagnostics are a key driver for the Next-generation Sequencing Services Market. As healthcare providers increasingly adopt genomic testing for disease diagnosis and treatment monitoring, the demand for sequencing services is surging. Next-generation sequencing enables the identification of genetic mutations associated with various diseases, including cancer, cardiovascular disorders, and infectious diseases. Market analysis indicates that the clinical diagnostics segment is poised for substantial growth, with estimates suggesting it could represent a significant portion of the overall market by 2030. This trend is further supported by regulatory approvals for genomic tests and the integration of sequencing technologies into routine clinical practice, thereby enhancing patient care and outcomes.

Technological Advancements in Sequencing Technologies

The Next-generation Sequencing Services Market is experiencing rapid growth due to continuous technological advancements. Innovations such as improved sequencing platforms and enhanced bioinformatics tools are driving efficiency and accuracy in genomic analysis. For instance, the introduction of single-cell sequencing technologies has revolutionized the understanding of cellular heterogeneity, allowing for more precise insights into complex biological systems. Furthermore, advancements in data processing capabilities have enabled the handling of vast amounts of genomic data, which is crucial for large-scale studies. As a result, the market is projected to expand significantly, with estimates suggesting a compound annual growth rate of over 20% in the coming years. This technological evolution not only enhances research capabilities but also broadens the application scope of next-generation sequencing in clinical diagnostics and personalized medicine.

Market Segment Insights

By Application: Clinical Diagnostics (Largest) vs. Drug Discovery (Fastest-Growing)

In the Next-generation Sequencing Services Market, the application segment showcases a diverse landscape. Clinical Diagnostics holds the largest share, primarily driven by its increasing adoption in genetic testing and disease diagnostics. Following closely is Drug Discovery, which is experiencing significant growth due to the rising demand for innovative therapies and personalized medicine solutions. As research continues to evolve, each segment's contribution to the overall market becomes clearer, with specialized uses defining their respective positions. Growth trends in this segment are strongly influenced by advancements in technology, decreasing sequencing costs, and increased funding for genomic research. Personalized Medicine and Genomic Research are gradually advancing as critical areas, reflecting a broader understanding of genetic factors in health and disease. Drug Discovery, in particular, is becoming a vital player, fueled by the need for faster and more efficient drug development processes. These trends indicate a dynamic and rapidly evolving market landscape poised for continued expansion.

Clinical Diagnostics (Dominant) vs. Drug Discovery (Emerging)

Clinical Diagnostics is currently the dominant application in the Next-generation Sequencing Services Market, providing essential insights in patient care through genetic testing and precision medicine approaches. Its robust position is rooted in the demand for accurate diagnoses and personalized treatment plans, enhancing patient outcomes significantly. On the other hand, Drug Discovery is emerging as a pivotal segment, leveraging advances in sequencing technology to expedite the development of novel therapeutics. This application benefits from collaborations between pharmaceutical companies and academic institutions, who are increasingly utilizing genomic data to inform their drug development processes. Both segments are integral to enhancing healthcare delivery and innovation, driving the market towards new avenues of research and application.

By Technology: Sequencing by Synthesis (Largest) vs. Ion Semiconductor Sequencing (Fastest-Growing)

The Next-generation Sequencing Services Market is primarily dominated by the Sequencing by Synthesis technology, which has captured the largest market share. This technique's widespread adoption is attributed to its high accuracy, efficiency, and cost-effectiveness in generating large volumes of sequencing data. On the other hand, Ion Semiconductor Sequencing is emerging rapidly, appealing to laboratories due to its simple workflow and fast run times, making it a competitive alternative in specific applications.

Technology: Sequencing by Synthesis (Dominant) vs. Ion Semiconductor Sequencing (Emerging)

Sequencing by Synthesis remains the dominant technology within the Next-generation Sequencing Services Market, known for its reliable and high-throughput capabilities suitable for various genomic applications. Laboratories favor this method due to the precision it provides in sequencing complex genomes and its extensive supportive ecosystem, including established platforms and reagents. Conversely, Ion Semiconductor Sequencing represents an emerging technology, characterized by its portability and fast processing times. This method is increasingly recognized for enabling rapid diagnostics and personalized medicine, providing a cost-effective solution for sequencing smaller genomes and targeted applications.

By End Use: Academic Research (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

The Next-generation Sequencing (NGS) Services Market is primarily driven by diverse end-use applications. Academic research constitutes the largest segment, fueled by advances in genomics and personalized medicine. Educational institutions utilize NGS for a broad spectrum of studies, from basic research to complex genome analysis. In contrast, pharmaceutical companies are emerging as the fastest-growing segment, capitalizing on NGS technologies for drug discovery, biomarker identification, and precision medicine initiatives, thus reshaping the industry landscape.

Academic Research (Dominant) vs. Pharmaceutical Companies (Emerging)

Academic research plays a pivotal role in the Next-generation Sequencing Services Market, enabling researchers to conduct groundbreaking studies that contribute to significant scientific advancements. The demand is driven by the need for innovative solutions to unravel complex biological questions. While pharmaceutical companies are rapidly embracing NGS for their developmental processes, characterized by robust investment in targeted therapies and precision medicine. These firms leverage NGS to enhance drug development efficiency and foster collaborations with academic institutions, positioning themselves effectively in a competitive market.

Get more detailed insights about Next-generation Sequencing Services Market

Regional Insights

North America : Innovation and Leadership Hub

North America continues to lead the Next-generation Sequencing Services Market, holding a significant market share of 9.0 in 2024. The region's growth is driven by robust investments in biotechnology, increasing demand for personalized medicine, and advancements in genomic research. Regulatory support from agencies like the FDA and NIH further catalyzes innovation, ensuring a conducive environment for market expansion. The competitive landscape is characterized by key players such as Illumina, Thermo Fisher Scientific, and Agilent Technologies, which are at the forefront of technological advancements. The U.S. and Canada are the leading countries, with a strong focus on research and development. The presence of established companies and a growing number of startups contribute to a dynamic market, fostering collaboration and innovation in sequencing technologies.

Europe : Emerging Market with Potential

Europe's Next-generation Sequencing Services Market is poised for growth, with a market size of 4.5 in 2024. The region benefits from strong governmental support for genomic research and healthcare initiatives aimed at improving patient outcomes. The European Union's Horizon 2020 program and various national funding schemes are pivotal in driving research and innovation in genomics, enhancing the demand for sequencing services. Leading countries in this region include Germany, the UK, and France, where significant investments in healthcare and biotechnology are evident. Key players like Roche and Qiagen are expanding their operations, contributing to a competitive landscape. The presence of numerous research institutions and collaborations between academia and industry further strengthens the market, positioning Europe as a vital player in the global sequencing landscape.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is witnessing rapid growth in the Next-generation Sequencing Services Market, with a market size of 3.0 in 2024. Factors such as increasing investments in healthcare infrastructure, rising awareness of personalized medicine, and government initiatives to promote genomics are driving this growth. Countries like China and India are at the forefront, with significant advancements in biotechnology and healthcare policies supporting market expansion. China, in particular, is home to key players like BGI Genomics, which is leading the charge in sequencing technologies. The competitive landscape is evolving, with both established companies and new entrants vying for market share. The region's diverse population and increasing healthcare needs present unique opportunities for growth, making Asia-Pacific a critical area for next-generation sequencing services.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region, with a market size of 1.5 in 2024, presents a unique landscape for Next-generation Sequencing Services. The growth is driven by increasing investments in healthcare and biotechnology, alongside a rising demand for advanced diagnostic tools. However, challenges such as limited infrastructure and regulatory hurdles can impede progress. Governments are beginning to recognize the importance of genomics in healthcare, leading to gradual improvements in policy frameworks. Countries like South Africa and the UAE are emerging as leaders in the region, with initiatives aimed at enhancing genomic research and healthcare services. The presence of international players is growing, but local companies are also beginning to establish themselves. Collaborative efforts between governments and private sectors are essential to unlock the region's potential in sequencing services.

Next-generation Sequencing Services Market Regional Image

Key Players and Competitive Insights

The Next-generation Sequencing Services Market is characterized by a dynamic competitive landscape, driven by rapid technological advancements and increasing demand for genomic research. Key players such as Illumina (US), Thermo Fisher Scientific (US), and BGI Genomics (CN) are at the forefront, leveraging their innovative capabilities to enhance service offerings. Illumina (US) focuses on expanding its product portfolio through strategic partnerships and acquisitions, while Thermo Fisher Scientific (US) emphasizes its commitment to integrating advanced technologies into its sequencing platforms. BGI Genomics (CN) appears to be capitalizing on its extensive research capabilities to penetrate emerging markets, thereby shaping the competitive environment through a blend of innovation and regional expansion.The market structure is moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of global economic fluctuations. The collective influence of these major companies fosters a competitive atmosphere where innovation and operational efficiency are paramount, allowing them to respond adeptly to market demands.
In November Illumina (US) announced a strategic partnership with a leading biotechnology firm to develop next-generation sequencing solutions tailored for personalized medicine. This collaboration is expected to enhance Illumina's capabilities in precision health, potentially positioning the company as a leader in this niche market. The strategic importance of this partnership lies in its potential to accelerate the adoption of genomic technologies in clinical settings, thereby expanding Illumina's market reach.
In October Thermo Fisher Scientific (US) launched a new sequencing platform that integrates artificial intelligence to streamline data analysis. This innovation is likely to enhance the efficiency of genomic research, allowing researchers to derive insights more rapidly. The introduction of AI-driven solutions signifies a shift towards more sophisticated analytical tools, which could redefine competitive dynamics in the market.
In September BGI Genomics (CN) expanded its operations into Southeast Asia by establishing a new facility aimed at providing sequencing services to local research institutions. This move not only signifies BGI's commitment to regional growth but also highlights the increasing importance of localized services in meeting the specific needs of diverse markets. Such expansions may enhance BGI's competitive positioning by fostering closer relationships with regional stakeholders.
As of December current trends in the Next-generation Sequencing Services Market indicate a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the necessity for companies to adapt and innovate continuously to maintain a competitive edge in a rapidly changing market.

Key Companies in the Next-generation Sequencing Services Market include

Future Outlook

Next-generation Sequencing Services Market Future Outlook

The Next-generation Sequencing Services Market is projected to grow at a 7.53% CAGR from 2025 to 2035, driven by advancements in genomics, personalized medicine, and increasing research funding.

New opportunities lie in:

  • Development of portable sequencing devices for field research applications. Expansion of bioinformatics services to enhance data analysis capabilities. Partnerships with pharmaceutical companies for drug discovery and development.

By 2035, the market is expected to be robust, driven by innovation and strategic collaborations.

Market Segmentation

Next-generation Sequencing Services Market End Use Outlook

  • Academic Research
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Clinical Laboratories
  • Healthcare Institutions

Next-generation Sequencing Services Market Technology Outlook

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Single-Molecule Real-Time Sequencing
  • Nanopore Sequencing
  • Other Technologies

Next-generation Sequencing Services Market Application Outlook

  • Clinical Diagnostics
  • Drug Discovery
  • Genomics Research
  • Agricultural Biotechnology
  • Personalized Medicine

Report Scope

MARKET SIZE 2024 18.0(USD Billion)
MARKET SIZE 2025 19.36(USD Billion)
MARKET SIZE 2035 40.0(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.53% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Illumina (US), Thermo Fisher Scientific (US), BGI Genomics (CN), Roche (CH), Agilent Technologies (US), Qiagen (DE), PerkinElmer (US), Oxford Nanopore Technologies (GB), Genomatix (DE)
Segments Covered Application, Technology, End Use
Key Market Opportunities Advancements in personalized medicine drive demand for innovative Next-generation Sequencing Services Market solutions.
Key Market Dynamics Technological advancements and regulatory changes drive growth in the Next-generation Sequencing Services Market.
Countries Covered North America, Europe, APAC, South America, MEA
Author
Author Profile
Garvit Vyas LinkedIn
Analyst

Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

Leave a Comment

FAQs

What is the projected market valuation of the Next-generation Sequencing Services Market by 2035?

<p>The market is projected to reach a valuation of 40.0 USD Billion by 2035.</p>

What was the market valuation of the Next-generation Sequencing Services Market in 2024?

<p>The overall market valuation was 18.0 USD Billion in 2024.</p>

What is the expected CAGR for the Next-generation Sequencing Services Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the market during this period is 7.53%.</p>

Which application segment is anticipated to have the highest growth in the Next-generation Sequencing Services Market?

<p>Genomic Research is expected to grow from 5.0 USD Billion in 2024 to 12.0 USD Billion by 2035.</p>

What are the key technologies driving the Next-generation Sequencing Services Market?

<p>Sequencing by Synthesis and Ion Semiconductor Sequencing are leading technologies, with projected valuations of 15.6 USD Billion and 9.8 USD Billion respectively by 2035.</p>

Which end-use segment is likely to contribute significantly to the market growth?

<p>Pharmaceutical Companies are projected to increase from 4.5 USD Billion in 2024 to 10.0 USD Billion by 2035.</p>

Who are the major players in the Next-generation Sequencing Services Market?

<p>Key players include Illumina, Thermo Fisher Scientific, BGI Genomics, and Roche, among others.</p>

What is the anticipated growth for the Drug Discovery application segment?

<p>The Drug Discovery segment is expected to grow from 3.0 USD Billion in 2024 to 7.0 USD Billion by 2035.</p>

How does the market for Nanopore Sequencing compare to other technologies?

<p>Nanopore Sequencing is projected to grow from 2.0 USD Billion in 2024 to 4.4 USD Billion by 2035, indicating a robust growth trajectory.</p>

What is the expected growth trajectory for the Clinical Diagnostics segment?

<p>The Clinical Diagnostics segment is anticipated to expand from 4.5 USD Billion in 2024 to 10.0 USD Billion by 2035.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions